Decoding Disease: The Biomarkers Driving Precision Medicine

RESHAPING HOW BIOMARKERS ARE FOUND AND USED The latest analytical technology provides clinicians with insight into new biomarkers to guide decisions and enhance patient care. Multiomics integration: Integrating genomics, proteomics, and metabolomics into a single process sheds light on disease networks and lets clinicians target pathways rather than just symptoms. Liquid biopsies: Analyzing circulating tumor DNA, exosomal proteins, and microRNAs from a simple blood draw allows real‑time cancer detection, treatment monitoring, and recurrence tracking. AI-driven discovery: Machine learning can process datasets generated by multiomics platforms, which accelerates discovery and enables patient-specific response modeling. THE BIOMARKERS DRIVING PRECISION MEDICINE DECODING DISEASE: Biomarkers act as guides that can confirm a diagnosis or predict how a patient will respond to treatment. This infographic highlights key biomarkers, the analytical techniques used during their discovery and validation, and recent advances that have pushed translational biomarker research forward. EACH BIOMARKER ANSWERS A DIFFERENT QUESTION THE ANALYTICAL TECHNIQUES BEHIND EVERY BIOMARKER Not all biomarkers do the same job. Depending on where a patient is in their care journey, a different type of biomarker is needed to guide the next decision. Turning a molecular signal into a clinically useful biomarker is a two-stage process. Firstly, you must find a promising candidate, then prove that it holds up under investigation. This process aims to identify measurable biological indicators that objectively reflect disease states, disease progression, or responses to therapeutic interventions. Genomics and transcriptomics: Next‑generation sequencing and microarrays identify DNA mutations, copy number variations, and gene expression patterns. Metabolomics: Nuclear magnetic resonance spectroscopy and mass spectrometry characterize small-molecule metabolites, which act as downstream indicators of physiological change. Proteomics: Mass spectrometry (including LC-MS/ MS) and gel electrophoresis map the protein landscape to reveal disease-specific proteins and post-translational modifications. PREDICTIVE Signal the likely benefit, or potential toxicity, of a specific treatment, such as HER2 status predicting trastuzumab response. PHARMACODYNAMIC Confirm that a biological response has occurred following a medical intervention or drug exposure. RISK Flag an individual’s potential to develop a disease before any symptoms appear. DIAGNOSTIC Detect or confirm the presence of a disease or condition, such as prostate-specific antigen (PSA) for prostate cancer. PROGNOSTIC Indicate how a diagnosed disease is likely to progress or recur over time, helping clinicians anticipate a patient’s disease course. Validation tests the robustness, reproducibility, and accuracy of discovered candidates in larger, independent patient cohorts. TARGETED PROTEOMICS: Multiple reaction monitoring via mass spectrometry selectively measures and validates specific candidate proteins. IMMUNOASSAYS: ELISA and Western blotting remain the standard workflows for quantifying and verifying targeted proteins across sample types. PCR: A targeted technique used to validate specific genetic or transcriptomic biomarkers identified through initial sequencing. BIOINFORMATICS AND AI: Multivariate analysis of largescale datasets minimizes false discovery rates and ensures findings are reproducible. DISCOVERY VALIDATION By Steven Gibney, PhD | Designed by Janette Lee-Latour TOGETHER, THESE APPROACHES PROVIDE RIGOROUS, COMPLEMENTARY VALIDATION OF CANDIDATE BIOMARKERS. BIOMARKER RESEARCH EQUIPS CLINICIANS WITH THE LATEST TOOLS, GIVING THEM THE POWER TO ACHIEVE FASTER DIAGNOSIS AND SMARTER TREATMENT. Sponsored by: